Surgical Blood Loss Clinical Trial
Official title:
Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy
Study Design:
Randomized Controlled Clinical Trial.
Study Population:
The study population will be a consecutive series of participants attending the Early Cancer
Detection Unit (ECDU) at Ain Shams University Maternity Hospital.
80 women who are scheduled to undergo a hysteroscopic myomectomy will be included and will
be randomized into two groups:
Group A: women will undergo a hysteroscopic myomectomy with the use of (TXA) Kapron in the
distention medium
Group B: women will undergo hysteroscopic myomectomy with the use of placebo(normal saline
in the distention medium).
Randomization will be performed using a Computer-generated randomization system.
The allocated groups will be concealed in serially-numbered sealed opaque envelopes that
will only be opened after recruitment.
Patient allocation will be performed prior to the induction of anesthesia by an independent
person, who will not otherwise be involved in this study.
The trial will be appropriately blinded; the participants, outcome assessors and the surgeon
performing the procedure will be blinded to the medication type, which will be used inside
the distention medium.
Therefore, this study will be a randomized double blind prospective clinical
Methodology:
1. Informed written consent obtained from the participant.
2. History
1. Personal history
2. Menstrual history
3. Detailed obstetric history
4. Surgical intervention especially uterine surgeries and any post-operative
complication
5. History of drug intake, especially hormonal treatment or anticoagulant therapy.
3. Routine preoperative investigations in addition to a serum pregnancy test if pregnancy
is suspected.
4. Physical examination including general, abdominal and pelvic examination.
5. Hysteroscopy will be performed in the early proliferative phase using normal saline as
a distention medium.
6. Only in intervention group (TXA group) KAPRON (Tranexamic acid) will be added to the
injected media.
- In intervention group 500 mg of Kapron for every 500 ml of distending media will
be added.
- In the control group, placebo .i.e. ,normal saline in the same form will be
injected inside every 500 ml of the distention medium.
7. The trial will be appropriately blinded; the participants, outcome assessors and the
surgeon performing the procedure will be blinded to the medication type, which will be
used inside the distention medium. Therefore, our study will be a randomized double
blind prospective clinical trial.
8. Intraoperative bleeding and quality of view will be observed.
9. A blood sample will be taken from each participant in both groups after 24 hours from
the end of the operation for both hemoglobin and hematocrit levels.
Types of outcome measures:
Primary outcome measures:
Estimated Blood loss defined as comparing the hematocrit and hemoglobin at base line
(preoperative ) and 24 hours after surgery with the Tranexamic acid compared to the control
group.
Secondary outcome measures:
The quality of view, duration of surgery, the volume of injected media, intraoperative
complications and the success of the completion of the operation will be secondary outcomes.
Status | Not yet recruiting |
Enrollment | 80 |
Est. completion date | January 2018 |
Est. primary completion date | August 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Subjects must be able to understand, and read and sign the study specific informed consent after fully explanation the nature of the study . 2. Subjects exhibit submucous myoma that are completely within the endometrial cavity or extend less than 50 percent into the myometrium (type 0,i)according to European Society Of Hysteroscopy (ESH). 3. The submucous myoma are less than 4 cm in diameter Exclusion Criteria: 1. Pregnancy 2. Active Pelvic Infection 3. Present or History of Cervical or Uterine Caner 4. Bleeding Diathesis or patient on anticoagulant 5. Contraindication and /or allergy to medication specified in the treatment protocol 6. History of ischemic heart disease 7. Patient with Cardiopulmonary, Hepatic , and renal diseases 8. Patient with metabolic disorders including diabetes 9. Patients with uterine septum or structural abnormality |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ain Shams University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Estimated blood loss by comparing changes in hemoglobin level | Estimated blood loss by comparing changes in hemoglobin level before hysteroscopic myomectomy (preoperative) and 24 hours after hysteroscopic myomectomy (postoperative) in Tranexamic acid group comparing to the control group | 24 Hours | |
Primary | Estimated blood loss by comparing changes in hematocrit level | Estimated blood loss by comparing changes in hematocrit level before hysteroscopic myomectomy (preoperative) and 24 hours after hysteroscopic myomectomy (postoperative) in the Tranexamic acid group comparing to the control group | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04588350 -
Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery
|
N/A | |
Completed |
NCT00985920 -
Topical Tranexamic Acid for Total Knee Arthroplasty
|
Phase 4 | |
Terminated |
NCT03954314 -
DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
|
Phase 3 | |
Completed |
NCT04040023 -
Patient Blood Management in Cardiac Surgery
|
N/A | |
Withdrawn |
NCT05672407 -
The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery
|
Phase 4 | |
Not yet recruiting |
NCT05379530 -
TEG Use in Children Undergoing Procedures With High Anticipated Blood Loss
|
N/A | |
Recruiting |
NCT03740438 -
Modeling of the Hemoglobin Drop in the Uncomplicated Postoperative Course
|
||
Completed |
NCT05708690 -
Topical Effect of Tranexamic Acid in Postoperative Bleeding and Blood Products Transfusion After Cardiac Surgery
|
Phase 4 | |
Completed |
NCT04143373 -
Effect of Warm Saline Irrigation on Bleeding in Mandibular Third Molar Surgery
|
N/A | |
Completed |
NCT02996006 -
New Techniques to Reduce Intra-operative Bleeding During Complex Liver Resection
|
N/A | |
Completed |
NCT03313583 -
French One Day Survey in 2011 - Knowing Our Population of Labile Blood Products Recipients
|
N/A | |
Completed |
NCT03952546 -
To Evaluate the Safety and Efficacy of the Saline-coupled Bipolar Sealer in Primary Unilateral Total Knee Arthroplasty
|
N/A | |
Active, not recruiting |
NCT03426839 -
Haemostasis Management of Abdominal Aortic Procedures
|
N/A | |
Completed |
NCT05780125 -
Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness
|
Phase 2 | |
Recruiting |
NCT06164769 -
Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery
|
N/A | |
Completed |
NCT04025736 -
Arthroscopic Shoulder Surgery With Administration of Intravenous Tranexamic Acid
|
N/A | |
Recruiting |
NCT02580227 -
Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures
|
Phase 4 | |
Terminated |
NCT03160170 -
Efficacy of Suction Enabled Retraction Device
|
N/A | |
Not yet recruiting |
NCT06414031 -
Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery
|
Phase 3 | |
Withdrawn |
NCT03340116 -
Measurement of Blood Volume Loss During Burn Surgery
|